A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. [electronic resource]
Producer: 20070906Description: 3951-9 p. digitalISSN:- 1078-0432
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antigen Presentation
- Antineoplastic Agents -- pharmacology
- CD8-Positive T-Lymphocytes -- metabolism
- Cancer Vaccines
- Cell Line, Tumor
- Flow Cytometry
- Humans
- Immune System
- Lymphocytes, Tumor-Infiltrating -- metabolism
- Mice
- Neovascularization, Pathologic
- Vascular Endothelial Growth Factor Receptor-2 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.